



## **Albireo to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 13, 2018**

November 6, 2018

BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that its third quarter financial results will be reported on November 13, 2018, prior to the open of U.S. financial markets. Management will host a conference call and live audio webcast at 8:30 a.m. EST on November 13 to review the results and provide a business update.

To access the live conference call by phone, dial 877-407-0792 (domestic) or 201-689-8263 (international) and provide the access code 13683207. A live audio webcast will be accessible from the Media & Investors page of Albireo's website, <http://ir.albireopharma.com/>. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the start time.

An archived version of the webcast will be available for replay on the Events & Presentations section of the Media & Investors page of Albireo's website for 1 year following the event.

### **About Albireo**

Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo's lead product candidate, A4250, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo's clinical pipeline also includes two Phase 2 product candidates. Albireo's elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008.

Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit [www.albireopharma.com](http://www.albireopharma.com).

### **Investor Contact:**

Hans Vitzthum  
LifeSci Advisors, LLC  
212-915-2568

### **Media Contact:**

Heather Anderson  
6 Degrees  
980-938-0260  
[handerson@6degreespr.com](mailto:handerson@6degreespr.com)

Source: Albireo Pharma, Inc.

 [albireo logo.jpg](#)

Source: Albireo Pharma, Inc.